Director — Andrew Levin, M.D., Ph.D.: Dr. Andrew Levin resigned as a Director of Vor Biopharma Inc.

Regulation FD Disclosure. On March 27, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933…

Entry into a Material Definitive Agreement. On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Pl…

The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each Investor has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for such Investor’s own account a…

Results of Operations and Financial Condition. On January 12, 2026, Vor Biopharma Inc. (the “Company”) released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company’s cash, cash equivalents and short-term investments were approximately $450 million. The cash, cash equivalents and short-term investments information above and in the Presentation is preliminar…

Chief Development Officer — Dr. Qing Zuraw: Dr. Qing Zuraw decided to pursue other opportunities and ended his employment with the company.

Director — Sarah Reed: Sarah Reed resigned from the Board, and Andrew Levin was appointed as a new independent Class II director.

The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for the Investor’s own ac…

Regulation FD Disclosure. On December 15, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1…

Entry into a Material Definitive Agreement. On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement…

The filing describes a stock option repricing, which is not related to any management change.

Other Events. On November 10, 2025, Vor Biopharma Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc. and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 10,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Equity Offe…

Chief Development Officer — Dr. Qing Zuraw: The amendment provides additional severance benefits for Dr. Zuraw.

Material Modification to Rights of Security Holders. On September 17, 2025, Vor Biopharma Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-20 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Special Meeting of Stockholders held on August 25, 2025. Pursuant to…

The filing pertains to an amendment and restatement of the equity incentive plan, not a management change.

Other Events. On August 27, 2025, in connection with the Company’s existing at-the-market sales program, the Company filed a prospectus supplement (“Prospectus Supplement”) to its effective shelf registration statement on Form S-3 (File No. 333-285969) (the “2025 Form S-3”). The 2025 Form S-3 replaced the prior registration statement on Form S-3 (File No. 333-263541) which expired in March 2025. The Company filed the Prospectus Supplement for the purpose of registering the offer and sale of s…

Director — Joshua Resnick, M.D.: Dr. Joshua Resnick resigned as a Director of Vor Biopharma Inc.

Director — Sven (Bill) Ante Lundberg: Dr. Sven (Bill) Ante Lundberg resigned from the Board of Directors.

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer — Sandesh Mahatme: The company hired a new CFO with extensive experience in the biopharmaceutical industry.

Entry into a Material Definitive Agreement. Telitacicept License Agreement On June 25, 2025, Vor Biopharma Inc. (the “ Company ”) and RemeGen Co., Ltd. (“ RemeGen ”) entered into a license agreement (the “ License Agreement ”) granting the Company exclusive rights to develop and commercialize RemeGen’s proprietary fusion protein product, telitacicept, and related products (the “ Licensed Products ”) outside of the People’s Republic of China (“ PRC ”), Hong Kong, Macau and Taiwan (“ Greater Ch…

CEO — Robert Ang: Dr. Robert Ang resigned from multiple senior roles including CEO and was succeeded by Jean-Paul Kress.

The RemeGen Warrant and the Pre-Funded Warrants have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. The RemeGen Warrantholder has represented that it is an institutional “accredited investor” as defined in Rule 501 under the Securities Act, that it is acquiring the RemeGen Warrant solely for its own account and not for the account of others, and not wit…

Termination of a Material Definitive Agreement. On June 20, 2025, the Company entered into a Termination Agreement (the “ Termination Agreement ”) with PPF Off 100 Cambridge Park Drive, LLC, a Delaware limited liability company (the “ Landlord ”), pursuant to which the Company and the Landlord agreed to terminate that certain lease agreement (as amended, the “ Lease ”) originally dated as of December 17, 2019, as amended by that certain First Amendment to Lease, dated as of June 15, 2021, and…

Principal Financial Officer and Principal Accounting Officer — Robert Ang, M.B.B.S., M.B.A.: Dr. Robert Ang was internally promoted to Principal Financial Officer and Principal Accounting Officer.

Chief Financial Officer and Chief Scientific Officer and Head of Technical Operations — Han Choi and Tirtha Chakraborty, PhD: The executives were terminated as part of a workforce reduction plan.